Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	CytomX Therapeutics	XBiotech	Amryt Pharma	AC Immune	Verona Pharma
Symbol	NASDAQ:CTMX	NASDAQ:XBIT	NASDAQ:AMYT	NASDAQ:ACIU	NASDAQ:VRNA
Price Information
Current Price	$8.16	$17.11	$11.07	$6.21	$5.92
52 Week Range	Buy	N/A	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.0	1.4	1.3	1.7
Analysis Score	3.4	0.0	3.4	3.5	3.5
Community Score	2.8	3.1	2.9	2.4	3.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.0	0.0	0.8
Earnings & Valuation Score	0.0	1.9	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	N/A	Buy	Buy	Buy
Consensus Price Target	$12.07	N/A	$38.00	$16.00	$19.33
% Upside from Price Target	47.93% upside	N/A	243.27% upside	157.65% upside	226.58% upside
Trade Information
Market Cap	$530.49 million	$513.03 million	$397.16 million	$451.18 million	$342.98 million
Beta	0.74	1.5	N/A	0.82	0.4
Average Volume	1,066,744	93,373	42,432	716,284	108,265
Sales & Book Value
Annual Revenue	$57.49 million	N/A	$58.12 million	$111.75 million	N/A
Price / Sales	9.23	N/A	6.83	4.04	N/A
Cashflow	N/A	N/A	N/A	$0.69 per share	N/A
Price / Cash	N/A	N/A	N/A	8.97	N/A
Book Value	$1.12 per share	$18.20 per share	N/A	$4.06 per share	$3.28 per share
Price / Book	7.29	N/A	∞	1.53	N/A
Profitability
Net Income	$-102,240,000.00	$668.63 million	N/A	$45.74 million	$-40,780,000.00
EPS	($2.26)	N/A	($0.86)	$0.60	($3.10)
Trailing P/E Ratio	N/A	1.19	N/A	N/A	N/A
Forward P/E Ratio	N/A	∞	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-58.13%	N/A	N/A	-392.56%	N/A
Return on Equity (ROE)	-94.20%	-7.07%	N/A	-23.88%	-115.93%
Return on Assets (ROA)	-13.79%	-6.67%	N/A	-21.85%	-73.68%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	0.04%
Current Ratio	3.34%	18.28%	N/A	18.10%	2.99%
Quick Ratio	3.34%	18.28%	N/A	18.10%	2.99%
Ownership Information
Institutional Ownership Percentage	77.87%	14.79%	15.42%	27.68%	54.51%
Insider Ownership Percentage	5.80%	30.98%	N/A	N/A	N/A
Miscellaneous
Employees	144	95	182	125	25
Shares Outstanding	65.01 million	29.98 million	35.88 million	72.65 million	57.94 million
Next Earnings Date	8/5/2021 (Estimated)	5/17/2021 (Estimated)	8/5/2021 (Estimated)	8/4/2021 (Estimated)	8/13/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Zacks: Brokerages Anticipate Verona Pharma plc (NASDAQ:VRNA) to Announce -$0.39 EPS americanbankingnews.com - May 11 at 11:26 PM
	Verona Pharma (NASDAQ:VRNA) PT Lowered to $18.00 at Canaccord Genuity americanbankingnews.com - May 10 at 10:30 AM
	Insider Selling: Verona Pharma plc (NASDAQ:VRNA) Director Sells 12,056 Shares of Stock americanbankingnews.com - May 5 at 8:30 PM
	Verona Pharma plc Forecasted to Post Q1 2022 Earnings of ($0.40) Per Share (NASDAQ:VRNA) americanbankingnews.com - May 5 at 4:38 AM
	Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference benzinga.com - May 4 at 2:43 AM
	Verona Pharma (NASDAQ:VRNA) PT Lowered to $18.00 americanbankingnews.com - May 3 at 12:09 PM
	FY2025 EPS Estimates for Verona Pharma plc Boosted by Analyst (NASDAQ:VRNA) americanbankingnews.com - May 3 at 4:52 AM
	Brokers Set Expectations for Verona Pharma plc's Q1 2022 Earnings (NASDAQ:VRNA) americanbankingnews.com - May 3 at 4:18 AM
	Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - April 29 at 7:49 AM
	Verona Pharma plc (NASDAQ:VRNA) Sees Large Growth in Short Interest americanbankingnews.com - April 29 at 1:28 AM
	Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International ... apnews.com - April 27 at 8:32 AM
	Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease finance.yahoo.com - April 27 at 8:32 AM
	Analysts Anticipate Verona Pharma plc (NASDAQ:VRNA) Will Announce Earnings of -$0.45 Per Share americanbankingnews.com - April 24 at 8:12 AM
	Zacks: Brokerages Anticipate Verona Pharma plc (NASDAQ:VRNA) to Announce -$0.45 Earnings Per Share americanbankingnews.com - April 24 at 8:12 AM
	Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 finance.yahoo.com - April 23 at 6:16 AM
	Verona Pharma (VRNA) Set to Announce Earnings on Thursday americanbankingnews.com - April 22 at 4:06 AM
	Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update feeds.benzinga.com - April 21 at 3:05 AM
	Revisiting Verona Pharmaceuticals seekingalpha.com - March 2 at 7:39 AM
	Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference markets.businessinsider.com - March 1 at 2:11 AM
	Verona Pharma plc 2020 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 26 at 1:49 PM
	Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ... apnews.com - February 26 at 8:21 AM
	Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update feeds.benzinga.com - February 25 at 2:58 AM
	Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide ... apnews.com - February 18 at 7:21 AM
	Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update markets.businessinsider.com - February 18 at 2:29 AM
	CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI ... apnews.com - February 2 at 7:25 AM

Date	Company	Brokerage	Action
3/29/2021	CytomX Therapeutics	Jefferies Financial Group	Upgrade
3/29/2021	CytomX Therapeutics	JPMorgan Chase & Co.	Initiated Coverage
11/8/2020	CytomX Therapeutics	Barclays	Reiterated Rating
9/22/2020	CytomX Therapeutics	Guggenheim	Downgrade
9/15/2020	CytomX Therapeutics	Citigroup	Lower Price Target
8/7/2020	CytomX Therapeutics	HC Wainwright	Reiterated Rating
5/29/2020	CytomX Therapeutics	Mizuho	Reiterated Rating
5/17/2020	CytomX Therapeutics	Nomura	Reiterated Rating
3/24/2020	CytomX Therapeutics	Wedbush	Upgrade
2/28/2020	CytomX Therapeutics	Nomura Securities	Lower Price Target
4/7/2020	XBiotech	Piper Sandler	Lower Price Target
12/11/2019	XBiotech	Piper Jaffray Companies	Boost Price Target
3/31/2021	Amryt Pharma	Maxim Group	Initiated Coverage
3/7/2021	Amryt Pharma	SVB Leerink	Reiterated Rating
11/2/2020	Amryt Pharma	Canaccord Genuity	Reiterated Rating
7/23/2020	Amryt Pharma	Cantor Fitzgerald	Initiated Coverage
2/1/2019	AC Immune	UBS Group	Downgrade
1/14/2020	Verona Pharma	SunTrust Banks	Boost Price Target
4/17/2019	Verona Pharma	BTIG Research	Initiated Coverage

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources